Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study-Reference-Cited by-同舟云学术

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Published:2021-04 Issue:4 Volume:22 Page:489-498
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rugo Hope S,Lerebours Florence,Ciruelos Eva,Drullinsky Pamela,Ruiz-Borrego Manuel,Neven Patrick,Park Yeon Hee,Prat Aleix,Bachelot Thomas,Juric Dejan,Turner Nicholas,Sophos Nickolas,Zarate Juan Pablo,Arce Christina,Shen Yu-Ming,Turner Stuart,Kanakamedala Hemanth,Hsu Wei-Chun,Chia Stephen

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer;André;N Engl J Med,2019

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

4. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline;Rugo;J Clin Oncol,2016

5. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer;Miller;J Clin Oncol,2011

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study;Journal of Clinical Oncology;2024-09-06

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?;ESMO Open;2024-09

4. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study;ESMO Open;2024-09

5. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09